Lv11
8 积分 2024-02-01 加入
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
6小时前
已完结
The next generation of antibody–drug conjugates
6小时前
已完结
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
7小时前
已完结
The present and future of bispecific antibodies for cancer therapy
9小时前
已完结
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy
4天前
已完结
BRAF/MEK inhibitors for redifferentiation in patients with radioiodine refractory thyroid cancer: A systematic review and Meta-Analysis
4天前
已完结
Selpercatinib-induced Redifferentiation and Enhanced Radioiodine Uptake in Radioiodine-refractory Thyroid Cancer
4天前
已完结
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
4天前
已完结
Feasibility of Short-Term Redifferentiation in Patients with Radioactive Iodine–Refractory Metastatic Thyroid Cancer
4天前
已完结
Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine
4天前
已完结
皖公网安备34019202002308
